$96.85
-0.12-0.12%
Last update: Nov 5, 10:56 AM
Mirum Pharmaceuticals Inc
MIRMNASDAQ
Mirum Pharmaceuticals (MIRM) earnings history, EPS estimates, revenue forecasts and company guidance.
Earnings Per Share (Non-GAAP)
Quarterly Revenue (Billions)
Mirum Pharmaceuticals (MIRM) last issued guidance on November 3, 2026 for fiscal year 2026. The company guided revenue in the range of $715M - $720M for the period.
Compared to prior guidance, Mirum Pharmaceuticals raised its revenue forecast from a prior range of $680M - $700M.
Mirum Pharmaceuticals has issued 14 guidance updates between November 9, 2022 and November 3, 2026. During this period, the company raised its outlook 10 times and lowered it 1 time, providing investors with insight into management's evolving expectations.
| Metric | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Estimate | $-0.44 | $-0.80 | $-0.36 | $0.04 |
| Actual | $-0.87 | $-0.80 | $-0.50 | $-0.12 |
| Surprise | -97.7% | 0.00% | -38.9% | -400.0% |
| Revenue | ||||
| Estimate | $177.7M | $165.5M | $148.2M | $141.6M |
| Actual | $185.7M | $176.2M | $159.9M | $148.9M |
| Surprise | +4.50% | +6.46% | +7.91% | +5.19% |
| Metric | Q4 '26E | Q1 '27E | Q2 '27E | Q3 '27E |
|---|---|---|---|---|
| Earnings Per Share (Non-GAAP) | ||||
| Consensus | $-0.47 | $-0.47 | $-0.16 | $-0.13 |
| Revenue | ||||
| Consensus | $192.4M | $192.2M | — | — |
| Fiscal Quarter | Date Reported | Actual EPS | Estimated EPS | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $-0.87 | $-0.44 | -97.7 % |
| Q2 | Aug 5, 2026 | $-0.80 | $-0.80 | 0.00 % |
| Q1 | May 6, 2026 | $-0.50 | $-0.36 | -38.9 % |
| Q4 | Feb 25, 2026 | $-0.12 | $0.04 | -400.0 % |
| Fiscal Quarter | Date Reported | Actual Revenue | Estimated Revenue | Surprise % |
|---|---|---|---|---|
| Q3 | Nov 3, 2026 | $185.72M | $177.72M | 4.50 % |
| Q2 | Aug 5, 2026 | $176.24M | $165.55M | 6.46 % |
| Q1 | May 6, 2026 | $159.88M | $148.17M | 7.91 % |
| Q4 | Feb 25, 2026 | $148.93M | $141.58M | 5.19 % |
